Research is moving toward the detection of reliable tools for predicting treatment efficacy and some studies have evaluated possible biomarkers both on tumor tissue (such as IDO, dMMR, tumor-infiltrating immune cells, mutational load and natural killer cells) and on peripheral blood (such as neutrophil-to-lymphocyte ratio) [16–19]. This evidence concerns the gene IDO1 and neoplasm.